Infliximab makes an impact in psoriatic arthritis

Infliximab [Remicade] is an effective treatment for psoriatic arthritis, according to data presented at the 63rd Annual Meeting of the American Academy of Dermatology (AAD). Results from the IMPACT 2 study showed that infliximab produced improvements in skin and joint symptoms, comparable to those observed in the IMPACT study. Importantly, improvements in skin symptoms were experienced by all patients, regardless of psoriasis severity at baseline. Furthermore, patients receiving infliximab also experienced improvements in physical function and productivity.